Lowering LDL-C important for younger patients

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • The risk for cardiovascular events linked to apolipoprotein B (apoB) particles decreases with age, underscoring the importance of therapy to lower low-density lipoprotein (LDL) levels for younger patients with elevated lipids.

Why this matters

  • High concentrations of the apoB lipoproteins increase the risk for cardiovascular disease.

Study design

  • Researchers determined the associations for total cholesterol, LDL‐cholesterol (LDL-C), non‐high‐density lipoprotein‐cholesterol (non‐HDL‐C), apoB, apolipoprotein A‐I (apoA‐I), and HDL‐C with myocardial infarction (MI) at different ages (11,760 control patients, 8998 patients with myocardial infarction [MI]).

  • They then used logistic regression to compute the MI OR for 1 SD change in each lipid marker by decade from <40 to >70 y of age.

  • Funding: The Doggone Foundation.

Key results

  • The cardiovascular risk associated with the atherogenic lipid markers differed at different ages.

  • There was a significant decline in the OR for total cholesterol, LDL‐C, non‐HDL‐C, and apoB with increases in age (P<.001); ORs associated with apoA‐I and HDL‐C were consistent across the age groups.


  • This was not a prospective observational study.